PARP1 and cancer: Depletion of PARP1 or both PARP1 and PARP2 compromised the survival of the HR-deficient cancer cells, mirroring the effect of the PARP inhibitors, whereas depletion of PARP2 had no effect (Extended Data Fig. 8).